Skip to content
Companies

Alpheus Medical

Ultrasound-activated drug therapy for glioblastoma

Raised to date

$60.5M

of $67M offered across 1 Form D filing

Still open
$6.5M
Investors
22
Last filed
Jul 30, 2026

About

Alpheus Medical is a clinical-stage company based in Chanhassen, Minnesota developing a non-invasive sonodynamic therapy (SDT) platform for solid tumors, starting with glioblastoma. Patients take an oral drug (5-ALA) that accumulates porphyrin metabolites preferentially in tumor cells, then low-intensity diffuse ultrasound is applied externally to activate those compounds, generating reactive oxygen species that kill tumor cells. The therapy is delivered in an outpatient setting with the patient awake and is designed for repeated dosing alongside standard-of-care surgery, radiation, and chemotherapy. A Phase 2b pivotal trial in newly diagnosed glioblastoma is enrolling, funded in part by an oversubscribed $52M Series B closed in May 2025.

Non-invasive drug-device combination that treats an entire brain hemisphere with low-intensity diffuse ultrasound plus oral 5-ALA — no surgery, implants, or head shaving — regulated through the FDA drug pathway and repeatable in an outpatient setting.

Funding

  • EquityFiled Jul 30, 2026Form D/A
    $60.5M/ $67M

Product

Sonodynamic Therapy (SDT) platform

Clinical-stage cancer therapeutic

An investigational drug-device combination pairing oral 5-aminolevulinic acid with proprietary low-intensity diffuse ultrasound (LIDU) to selectively destroy cancer cells across the brain hemisphere without harming healthy tissue.

  • Oral 5-ALA drug that concentrates porphyrin metabolites in tumor cells
  • Low-intensity diffuse ultrasound (LIDU) activation applied externally
  • Outpatient administration with the patient awake

Built for

Patients with newly diagnosed glioblastoma and the neuro-oncology centers treating them

People on file